



PHARMACY BULLETIN

HOSPITAL PERMAI JOHOR BAHRU

VOL 2/2020



Inside This Issue



Drug Information Services
Pharmacy Unit
Hospital Permai Johor Bahru
Persiaran Kempas Baru
Kempas Banjaran
81200 Johor Bahru
Johor, Malaysia
Tel: 607-2311000
Fax: 607-2366897

HIGHLIGHT

Rabies Infection

MEDICATION SAFETY

Gabapentin & Risk of Dysphagia
Propofol & Risk of Priapism

KNOW YOUR MEDICINE

Vaccine & Vaccination Schedule

ADVERSE DRUG REACTION

Immunization Anxiety Related Reactions

COUNSELLING POINTS


Warfarin

FORMULARI UBAT-UBATAN KKM

Pindaan/Tambahan Bil. 01/2020

PHARMACY ACTIVITIES

June - November 2020



EDITORIAL BOARD

Advisor

Siti Fatimah Binti Abu Bakar

Chief Editor(s)

Wong Yoke Mei

Vikneswari A/P Subramaniam

Co – Editors

Fam Hwei Teng

Syafizawati Binti Ghazali

Tan Woei Yan

Diviyasri A/P S. Soundra Rajan

Ng Hwee San

HIGHLIGHT

Article by Diviyasri

RABIES - Current Situation & Information

In Malaysia : Rabies has occurred since 1884 and was successfully eradicated in 1999. In year 2015, rabies cases among dogs were reported and the first case of rabies in human was reported on 1st July 2017 in Sarawak. Since then, a total of 24 confirmed human cases of rabies have been reported (in Sarawak), with 23 deaths.

RABIES (PENYAKIT ANJING GILA)

APAKAH ITU RABIES?

Rabies adalah penyakit sistem saraf yang disebabkan oleh jangkitan virus.

Virus ini merebak daripada haiwan kepada manusia. Kebiasaannya melalui :

- Luka gigitan haiwan
- Luka terbuka pada kulit dari air liur haiwan
- Cairan atau tisu tubuh dari haiwan



TANDA DAN GEJALA RABIES



Pesakit hanya menunjukkan tanda-tanda penyakit Rabies 20-90 hari selepas gigitan haiwan (tempoh peneraman).

- Demam
- Sakit dan lenguh pada tempat gigitan
- Kelesuan otot badan
- Sakit kepala

Gejala berlaku apabila virus telah menyerang sistem saraf pusat

- Keresahan dan kegelisahan
- Perubahan sikap secara tiba-tiba
- Kekeliruan
- Ketakutan terhadap air
- Kesukaran menelan
- Insomnia
- Lumpuh



PENCEGAHAN JANGKITAN RABIES

- **Jangan mendekati haiwan liar untuk mengurangkan risiko digigit terutamanya kanak-kanak.**

APAKAH TINDAKAN YANG PERLU DIBUAT JIKA ANDA DIGITIT?



SEGERA CUCI BAHAGIAN TUBUH YANG DIGITIT DENGAN SABUN DAN AIR BAGI MENGHILANGKAN KESAN AIR LIUR

- Segera dapatkan rawatan luka di klinik kesihatan / hospital berhampiran.
- Patuhi arahan doktor, sekiranya diperlukan, suntikan vaksin anti-rabies mengikut jadual suntikan


Reference

1. Disease Control Center, MOH: Interim Guideline for human rabies prevention & control in Malaysia. Retrieved from: https://www.moh.gov.my/moh/resources/Penerbitan/Interim_Guideline_for_Prevention_and_Control_of_Human_Rabies_in_Malaysia.pdf
2. Navanithakumar B. et.al., (2019) An overview of Rabies Outbreaks In Malaysia, Ordinance and Laws. Malaysian Journal of Veterinary Research, Vol. 10. Pages 148-158. Retrieved from: [http://www.dvs.gov.my/dvs/resources/user_16/MJVR%20Vol.10%20No.2%20\(2019\)/MJVR-V10N2-p148-158.pdf](http://www.dvs.gov.my/dvs/resources/user_16/MJVR%20Vol.10%20No.2%20(2019)/MJVR-V10N2-p148-158.pdf)

MEDICATION SAFETY

Article by Fam Hwei Teng

PROPOFOL & Risk of PRIAPISM



PROPOFOL
Indicated for the induction & maintenance of general anesthesia or sedation in children and adults during surgical or other diagnostic procedures.

Common SIDE EFFECTS

- ⇒ Local pain on induction
- ⇒ Hypotension
- ⇒ Bradycardia
- ⇒ Transient apnoea during induction
- ⇒ Nausea & vomiting
- ⇒ Diarrhea during recovery phase
- ⇒ Flushing

PRIAPISM : A pathologic, prolonged, painful erection of the penis without sexual stimulation. In most cases, it requires a prompt evaluation and emergency management.

The National Pharmaceutical Regulatory Agency (NPRA) has received information from Health Canada on the risk of priapism associated with the use of propofol.

In a safety review, Health Canada has reviewed one (1) local report and ten (10) international published reports of priapism that were linked to the use of propofol-containing products.

Majority of the reports (9) stated that the time to onset for priapism were between 5 minutes to 2 hours after propofol administration.

Most of the reports (10) stated that the patients recovered after receiving treatment while one (1) reported a long-term disability.

To date, the NPRA has received a total of 77 reports with 128 adverse events suspected to be related to propofol containing products.

However, no ADR related to priapism following the use of propofol has been reported locally.

GABAPENTIN & Risk of DYSPHAGIA

DYSPHAGIA : Difficulty in swallowing.

Gabapentin potentially causes dysphagia by depressing the central nervous system (CNS) which may lead to reduced awareness, reduced control of the voluntary muscle and difficulty to initiate a swallow.

National Pharmaceutical Regulatory Agency (NPRA) has received information from the European Medicines Agency (EMA) regarding Pharmacovigilance Risk Assessment Committee's (PRAC) recommendation to all product registration holders of gabapentin to update the package insert with risk of dysphagia.

In Malaysia, the **Drug Control Authority (DCA)** has agreed to the inclusion of dysphagia in the post marketing experience section of the package insert of all gabapentin-containing products.

To date, NPRA has received 377 reports with 681 adverse events suspected to be related to gabapentin.

However, no events related to dysphagia or difficulty swallowing have been reported locally.



GABAPENTIN
Indicated for epilepsy and neuropathic pain.

Common SIDE EFFECTS

- ◆ Somnolence
- ◆ Ataxia
- ◆ Nystagmus
- ◆ Weight gain
- ◆ Fatigue & Myalgia
- ◆ Headache & Dizziness
- ◆ Diplopia
- ◆ Amnesia
- ◆ Tremor
- ◆ Dyspepsia
- ◆ Asthenia
- ◆ Leukopenia

Reference


1. National Pharmaceutical Regulatory Agency. The Malaysian National ADR Database [Internet]. 2020 [Cited 2020 October 22]. Available from: <https://www.npra.gov.my> .pdf
2. Health Canada. Summary Safety Review – Propofol-containing products – Assessing the potential risk of prolonged erection of the penis (priapism) [Internet]. 2019 July 12 [Cited on 2020 October 22]. Available from: http://www.nanb.nb.ca/media/news/EN_Propofol_containing_products_priapism_SSR_PDF.PDF

KNOW YOUR MEDICINE

Article by Tan Woei Yan

VACCINE

- ⇒ A vaccine is a dead, weakened or part of the germ that causes the disease.
- ⇒ When people are exposed to a disease in vaccine form, immune system will build up antibodies that protect the body from contracting the disease when exposed to the actual disease.
- ⇒ **VACCINATION PROTECTS PEOPLE** from deadly diseases, such as polio, tetanus, and diphtheria.
- ⇒ Common unwanted effects of vaccine include pain, swelling and redness at site of injection, mild fever, chills, lethargy, headache, muscle and joint pain.



TYPE OF VACCINE	EXAMPLE
LIVE ATTENUATED	Tuberculosis, Oral Polio Vaccine, Measles, Rotavirus, Yellow Fever
INACTIVATED (KILLED ANTIGEN)	Whole-cell Pertussis, Inactivated Polio Virus
SUBUNIT (PURIFIED ANTIGEN)	Acellular Pertussis, Haemophilus Influenza Type B, Pneumococcal, Hepatitis
TOXOID (INACTIVATED TOXINS)	Tetanus Toxoid, Diphtheria Toxoid

IMMUNIZATION SCHEDULE - MALAYSIA

VAKSIN	Umur (Bulan)											Umur (Tahun)		
	Lahir	1	2	3	5	6	9	12	18	21	7	13	15	
BCG	■													
Hepatitis B	■													
Difteria-Tetanus- Pertussis – Polio – Hepatitis B - Haemophilus influenzae type b (DTaP-IPV-HepB-Hib)			Dos 1	Dos 2	Dos 3				Dos penggalak (booster)					
Measles (Sabah sahaja)						■								
Measles – Mumps – Rubella (MMR)							■	■						
Japanese Encephalitis (JE) (Sarawak sahaja)							■			■				
Measles-Rubella (MR)											■			
Difteria – Tetanus (DT)											■			
Human Papilloma Virus (HPV)												2 dos		
Tetanus (ATT)													■	

Seluruh negara
 Negeri tertentu sahaja
 Terkini: 17/11/2020

Reference

- Jadual Immunisasi kanak-kanak (terkini). Retrieved from <https://kpkesehatan.com/2020/11/17/kenyataan-akhbar-kpk-17-november-2020-pertukaran-jadual-imunisasi-kebangsaan-untuk-kanak-kanak-susulan-pertukaran-kepada-vaksin-enam-serangkai-difteria-tetanus-pertussis-polio-hepatitis-b/>
- Chronicle, D., Malaysia, I., & Editor, T. (2015, June 17). Vaccination in Malaysia. Retrieved October 25, 2020, from <http://infomed.com.my/vaccination-in-malaysia>

ADVERSE DRUG REACTION

Article by Syafizawati Ghazali

IMMUNIZATION ANXIETY Related Reactions

- ◇ According to WHO (2018), Immunization anxiety related reactions are **ADVERSE EVENTS FOLLOWING IMMUNIZATION (AEFI)**, arising from anxiety about the immunization and unrelated to the components of the vaccine.
- ◇ The reactions can take place just before, during, or after immunization immediately.
- ◇ The signs and symptoms of the reaction are brief and can resolve spontaneously.
- ◇ **The National Pharmaceutical Regulatory Agency (NPRA)** has received 14 AEFI reports categorized as Immunization anxiety-related reactions, involving patients between the ages of 6-19 years old.
- ◇ The AEFI reported includes dizziness, syncope or fainting, non-epileptic seizure, sweating, vomiting, pallor, nausea and hyperventilation.
- ◇ To avoid false diagnosis between anaphylaxis and fainting, the clinical features should be differentiated carefully by the physicians.

FAINTING VS ANAPHYLAXIS

CLINICAL FEATURES	FAINTING	ANAPHYLAXIS
TIME	Before, during or a few minutes after injection	A short time, up to a few hours
SKIN	Generalized pallor, cold clammy skin	Itching, generalized erythema, urticaria, lips swelling and face, tingling around lips
RESPIRATORY SYSTEM	Normal/shallow breathing	Tachypnoea, difficulty in breathing, wheezing, stridor, hoarseness, cyanosis, recession of intercostal spaces
CARDIOVASCULAR SYSTEM	Bradycardia, weak pulse, carotid pulse felt, hypotension may occur and may reversed by supine position	Tachycardia, weak pulse, carotid pulse may be weak, hypotension may not be reversed by supine position
GASTROINTESTINAL SYSTEM	Vomiting	Vomiting, diarrhoea, abdominal cramps
CENTRAL NERVOUS SYSTEM	Feeling faint, light-headedness relieved by supine position	Anxiety and distress, loss of consciousness not relieved by supine position

Article mainly adapted & reproduced from MADRAC BULLETIN 3/2019

Reference

1. World Health Organisation (2015). Immunization safety surveillance: Guidelines for immunization programme managers on surveillance of adverse events following immunization, 3rd edition.
2. <https://www.who.int/> (Accessed on 27 October 2020) World Health Organisation (2020). Global Vaccine Safety: Immunization stress-related responses.
3. National Pharmaceutical Regulatory Agency, MADRAC Bulletin Vol. 30, Issue 03/2019. Available online at <https://www.npra.gov.my/>

COUNSELLING POINTS

Article by Ng Hwee San

WARFARIN

- ◇ Is an anticoagulant prescribed for patients who are at increased risk for developing harmful blood clots, in order to prevent the formation of new blood clots and prevent existing blood clots from getting larger.
- ◇ Mode of action of warfarin: Interferes with the synthesis of vitamin K-dependent clotting factors.

WARFARIN is indicated for :

- ◇ Deep Vein Thrombosis
- ◇ Pulmonary Embolism
- ◇ Atrial Fibrillation
- ◇ Heart Valve Replacement.
- ◇ Other indications :
 - ⇒ Cardiomyopathy
 - ⇒ Anti-phospholipid Syndrome
 - ⇒ Post Myocardial Infarction



DOSE & DURATION

- ◇ based on indication and International normalized Ratio (INR) target.
- ◇ INR: shows the rate of blood clotting in the body.
- ◇ **THE HIGHER YOUR INR IS, THE LONGER IT TAKES FOR YOUR BLOOD TO CLOT.**
- ◇ Target INR: 2-3 (except for stroke prophylaxis in patients with mechanical heart valves: INR of 2.5-3.5).

IMPORTANT COUNSELLING POINTS!

1. WARFARIN must be taken at the **SAME TIME EVERY DAY**.
2. If **MISSED A DOSE** for more than 8 hours, skip the dose and take the next dose.
3. Follow the scheduled blood test and the counselling appointment made to achieve targeted INR.
4. Bring along anticoagulant booklet and all medications during the doctor/pharmacist appointment.
5. Advise patient to **REMEMBER THE DOSE**, not the colour of tablet.
6. To inform healthcare professionals if patient is planning to get pregnant, tooth extraction, or when getting consultation for medication, supplement or herbal remedies.
7. Report to doctor and pharmacist if any sign or symptom of bleeding occurs.
8. **AVOID HAZARDOUS ACTIVITIES** that could result in serious lacerations or blunt trauma.
9. Consult doctor and pharmacist before starting, stopping or changing dose of any medication/supplement.
10. Monitor and maintain consistent intake of food which are rich in vitamin K such as green leafy vegetables.
11. Advise to only consume small quantity of alcohol, stop smoking and manage stress.
12. Advise women with childbearing age that warfarin can have adverse effects on fetal development (first trimester), hence, to inform doctor if planning to get pregnant.

Reference

1. Hanafi, N.I. (2014, April 23). Warfarin. Retrieved October 24, 2020, from <http://www.myhealth.gov.my/en/warfarin-2/>
2. Bahagian Perkhidmatan Farmasi Kementerian Kesihatan Malaysia. Buku Rawatan Antikoagulasi (Warfarin)
3. Pharmaceutical Services Programme, Ministry of Health, Malaysia. (2019). Garis Panduan Kauseling Ubat-ubatan Edisi Ke-3.

PINDAAN FORMULARI UBAT KKM

Adapted from Circular FUKKM 01/2020

New Drugs Approved to be Listed in FUKKM

Drug Name	Prescriber Category	Approved Indication(s)	Dose
Mirabegron 50mg Prolonged Release Tablet	A*	For symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Prescribing Restricted to patients who are not responsive, intolerant or unsuitable to use other existing agents.	50mg Once daily. Should be taken once daily, with liquid, swallowed whole and is not to be chewed, divided, or crushed.
Pneumococcal Polysaccharide and Non-Typeable Haemophilus Influenzae (NTHi) Protein D Conjugate Vaccine (10-valent, adsorbed)	C+	Active immunization of infants and children against disease caused by Streptococcus Pneumoniae vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F and cross-reactive serotype 19A (including sepsis, meningitis, pneumonia, bacteraemia and acute otitis media) and against acute otitis media caused by Non-Typeable Haemophilus influenzae. Prescribing Restricted to immunization for newborn cohort eligible for National Immunization Programme	2-dose primary series (2+1): A series consisting of 3 doses, each of 0.5 ml may be given. Dosing is according to Immunization Schedule under National Immunization Programme.

PINDAAN FORMULARI UBAT KKM

Adapted from Circular FUKKM 01/2020

Additional Indication Approved for Drug Listed in FUKKM

Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed)		
Prescriber Category	Approved to add Indication(s)	Dose
<p>C+: For indication 1. (i)</p> <p>A*: For indication 1. (ii)</p>	<p>Active immunization for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (including invasive disease, pneumonia and acute otitis media) in infants, children and adolescents from 2 months to 17 years of age.</p> <p>Prescribing Restriction:</p> <p>i) Immunization for newborn cohort eligible for National Immunization Programme</p> <p>ii) Paediatric population without history of vaccination or not eligible for NIP, who have associated risk in IPD with following conditions:</p> <p>a) Infants/children from 2 months of age with one of the following conditions:</p> <ul style="list-style-type: none"> • Functional or Anatomical Asplenia; • Cochlear implant; • Congenital immune-deficiency; • Haematopoietic and solid organ transplant; • Cerebrospinal fluid leakage** <p>b) High risk infants/children from 2 months old with one of the following conditions:</p> <ul style="list-style-type: none"> • Immunosuppression (including asymptomatic HIV) • Nephrotic syndrome • Chronic lung or heart disease (adapted from Paediatric Protocols for Malaysia Hospital, 3rd Edition) • Chronic liver disease** <p>**Newly Added Indication</p>	<p>2-dose primary series (2+1): A series consisting of 3 doses, each of 0.5 ml may be given.</p> <p>Dosing is according to Immunization Schedule under National Immunization Programme .</p>

PINDAAN FORMULARI UBAT KKM

Adapted from Circular FUKKM 01/2020

Additional Indication Approved for Drug Listed in FUKKM

Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed)		
Prescriber Category	Approved to add Indication(s)	Dose
A*	<p>Active immunization for the prevention of pneumococcal disease caused by <i>Streptococcus pneumoniae</i> serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adults aged 18 years and older.</p> <p>Prescribing restrictions:</p> <p>i) Adult population aged 18 years and above with associated risk in IPD with following conditions:</p> <ul style="list-style-type: none">a) Functional or Anatomical Asplenia;b) Cochlear Implant;c) Congenital Immune-Deficiency;d) Haematopoietic and Solid Organ Transplant. <p>ii) Adult population aged 60 years and above with associated risk in IPD with following conditions:</p> <ul style="list-style-type: none">a) Chronic lung diseases, including chronic obstructive pulmonary disease (COPD), emphysema & asthma (requiring frequent hospital visit & use of multiple medications);b) Chronic liver disease including cirrhosis, biliary atresia, chronic hepatitis;c) Chronic cardiac disease, including congestive heart failure, congenital heart disease, and cardiomyopathies.	<p>2-dose primary series (2+1): A series consisting of 3 doses, each of 0.5 ml may be given.</p> <p>Dosing is according to Immunization Schedule under National Immunization Programme.</p>

PINDAAN FORMULARI UBAT KKM

Adapted from Circular FUKKM 01/2020

Additional Indication Approved for Drug Listed in FUKKM

Salbutamol 0.5mg/ml Injection (Multisource)		
Prescriber Category	Approved to add Indication(s)	Dose
A	For prevention of uncomplicated premature labour only	Infusions containing 5 mg in 500ml (10 mcg/ml) at the rate of 10 - 45 mcg/min increased at intervals of 10 minutes until evidence of patient response as shown by reduction of strength, frequency or duration of contractions; maintain rate for 1 hour after contractions have stopped, then gradually reduce by 50% every 6 hours.
Salbutamol 5mg/5ml Injection (Multisource)		
Prescriber Category	Approved to add Indication(s)	Dose
A*	Asthma or other conditions associated with reversible airway obstruction	500 mcg by SC/IM injection 4 hourly or 250 mcg by slow IV. If required, by IV infusion, initially 5 mcg/min adjusted according to response and heart rate, usually in the range 3 - 20 mcg/min.

PINDAAN FORMULARI UBAT KKM

Adapted from Circular FUKKM 01/2020

New Formulation Approved to be Added for Drug Listed in FUKKM

Desmopressin 60mcg & 120 mcg Sublingual Tablet		
Prescriber Category	Approved Indication(s)	Dose
A	i) Central Diabetes Insipidus ii) Primary Nocturnal Enuresis iii) Treatment of Nocturia Associated with Nocturnal Polyuria in Adults Precaution(s): * Patients with urgency/urge incontinence, polydipsia and poorly adjusted diabetes mellitus; * patients with increased risk for hyponatraemia and intracranial pressure; * patients with acute illnesses characterised by fluid and/or electrolyte imbalance.	i) Central Diabetes Insipidus: 60mcg 3 times daily sublingually (daily dose range from 120mcg to 720mcg) ii) Primary Nocturnal Enuresis: 120mcg once daily at bedtime, sublingually (maximum dose 240mcg) iii) Treatment of Nocturia Associated with Nocturnal Polyuria in Adult: 60mcg once daily at bedtime (dose range from 120mcg to 240mcg)

Changes in Prescriber Category Approved for Drug Listed in FUKKM

Drug Name	Previous Prescriber Category	New Prescriber Category
Rosuvastatin 10 mg and 20mg Tablets	A*	A/KK
Fusidic Acid 2% Cream	A	B

PINDAAN FORMULARI UBAT KKM

Adapted from Circular FUKKM 01/2020

Drugs Approved to be Delisted from FUKKM

Drug Name	Alternative Drug Available in FUKKM
Flavoxate HCl 100 mg Tablet	<ul style="list-style-type: none"> ◆ Solifenacin Succinate 5 mg Tablet ◆ Tolterodine Tartrate ER 4 mg Capsule ◆ Propiverine HCl 15 mg Tablet ◆ Mirabegron 50 mg Prolonged Released Tablet
Deferasirox 125 mg Dispersible Tablet Deferasirox 500 mg Dispersible Tablet	<ul style="list-style-type: none"> ◆ Deferasirox 90 mg & 360 mg Film Coated Tablets ◆ Deferiprone 500 mg Tablet ◆ Desferrioxamine 0.5g Injection
Oxycodone Prolonged Release 10 mg Tablets Oxycodone Prolonged Release 20 mg Tablets Oxycodone Prolonged Release 40 mg Tablets	<ul style="list-style-type: none"> ◆ Oxycodone Controlled Release 10 mg, 20 mg & 40 mg Tablets
Erythromycin Stearate 250 mg Tablet	<ul style="list-style-type: none"> ◆ Erythromycin Ethylsuccinate 400 mg Tablet
Cefoperazone Sodium 500 mg Injection	<ul style="list-style-type: none"> ◆ Cefoperazone 1 g Injection ◆ Cefepime 2 g Injection
Ceftazidime 250 mg Injection Ceftazidime 200 mg Injection	<ul style="list-style-type: none"> ◆ Ceftazidime 1 g & 2 g Injection
Metronidazole 0.5 g Suppository	<ul style="list-style-type: none"> ◆ Metronidazole 200 mg Tablet ◆ Metronidazole 200mg/5mL Suspension ◆ Metronidazole 500mg/100mL Injection
Pefloxacin 400 mg Injection	<ul style="list-style-type: none"> ◆ Ciprofloxacin 100mg Injection ◆ Ciprofloxacin 200mg Injection ◆ Moxifloxacin 400mg Injection ◆ Levofloxacin 500mg Injection ◆ Ofloxacin 200mg Injection
Pefloxacin 400 mg Tablet	<ul style="list-style-type: none"> ◆ Levofloxacin 250mg Tablet ◆ Levofloxacin 500mg Tablet ◆ Ciprofloxacin 250mg Tablet ◆ Ciprofloxacin 500mg Tablet ◆ Moxifloxacin 400mg Tablet ◆ Ofloxacin 100mg Tablet
Procaine Benzylpenicillin Aqueous 3 MU (3 g) Injection	<ul style="list-style-type: none"> ◆ Procaine Penicillin Fortified 4 MU Injection
Cefepime 500 mg Injection	<ul style="list-style-type: none"> ◆ Cefepime 1g Injection
Cefuroxime Sodium 250 mg Injection	<ul style="list-style-type: none"> ◆ Cefuroxime 750mg & 1.5g Injection
Cefaclor 375 mg MR Tablet	<ul style="list-style-type: none"> ◆ Other cephalosporins <ul style="list-style-type: none"> ⇒ Cefuroxime Axetil 125mg & 250mg Tablets ⇒ Cefuroxime Axetil 125mg/5mL Suspension ⇒ Cephalexin Monohydrate 250mg & 500mg Capsule / Tablet ⇒ Cephalexin Monohydrate 125mg/5mL Syrup

PINDAAN FORMULARI UBAT KKM

Adapted from Circular FUKKM 01/2020

Drugs Approved to be Delisted from FUKKM

Drug Name	Alternative Drug Available in FUKKM
Doripenem Monohydrate 500 mg Injection	<ul style="list-style-type: none"> ◆ Meropenem 500mg & 1g Injection ◆ Imipenem 500 mg and Cilastatin 500 mg Injection ◆ Ertapenem 1g Injection
Gentamicin sulfate 7.5 mg Beads	<ul style="list-style-type: none"> ◆ Gentamicin Sulphate 40mg/MI Injection
Nifedipine 10 mg Capsule	<ul style="list-style-type: none"> ◆ Nifedipine 10mg Tablet
Dihydroergocristine or Co-dergocrine Mesilate 1mg Tablet	<p>Dementia</p> <ul style="list-style-type: none"> ◆ Donepezil 5mg & 10mg Tablet ◆ Donepezil 10mg Orodispersible Tablet ◆ Rivastigmine 1.5mg, 3mg, 4.5mg 6mg Capsule <p>Migraine Prophylaxis</p> <ul style="list-style-type: none"> ◆ Propranolol 10mg & 40mg Tablet ◆ Flunarizine 5mg Capsule
Isosorbide Mononitrate (ISMN) 50 mg SR Capsule	<ul style="list-style-type: none"> ◆ ISMN 60mg SR Tablet
Isosorbide-5-Mononitrate (ISMN) 30 mg SR Tablet	<ul style="list-style-type: none"> ◆ ISMN 60mg SR Tablet
Modified Polypeptides (Polygeline) 3.5% Injection	<ul style="list-style-type: none"> ◆ Modified Fluid Gelatin 4%
Selected Plasma Protein 5 g/100 ml Injection	<ul style="list-style-type: none"> ◆ Hydroxyethyl Starch 6% Injection
Dextran 40 Injection	<ul style="list-style-type: none"> ◆ Sodium Chloride 0.45% with ◆ Dextrose 5% Injection ◆ Dextrose 5% Injection ◆ Human Albumin Injection
Tinzaparin Sodium 10,000 Factor Xa IU/ml Injection Tinzaparin Sodium 20,000 Factor Xa IU/ml Injection	<ul style="list-style-type: none"> ◆ Enoxaparin ◆ Heparin ◆ Fondaparinux
Bupivacaine 0.125% Epidural Injection	<ul style="list-style-type: none"> ◆ Bupivacaine 2.5% Injection ◆ Bupivacaine 5% Injection ◆ Levobupivacaine 5mg/ml Injection
Tramadol HCl 100 mg Suppository Tramadol HCl 100 mg/ml Drops	<ul style="list-style-type: none"> ◆ Tramadol Tablet, Capsules and Injection
Ziprasidone 20 mg/ml Injection	<ul style="list-style-type: none"> ◆ Haloperidol 5mg Injection ◆ Zuclopenthixol 50mg Accuphase Injection ◆ Olanzapine Orodispersible Tablet (all strengths)

PINDAAN FORMULARI UBAT KKM

Adapted from Circular FUKKM 01/2020

Drugs Approved to be Delisted from FUKKM

Drug Name	Alternative Drug Available in FUKKM
Imipramine HCl 25 mg Tablet	<p>Tricyclic Antidepressants</p> <ul style="list-style-type: none"> ◆ Clomipramine 25mg Tablet ◆ Amitryptilline 25mg Tablet ◆ Dothiepin 25mg & 75mg Tablet <p>Selective Serotonin Reuptake Inhibitors</p> <ul style="list-style-type: none"> ◆ Fluvoxamine 100mg Tablet ◆ Fluoxetine 20mg Capsule ◆ Sertraline 50mg Tablet ◆ Escitalopram 10mg Tablet <p>Serotonin and Norepinephrine Reuptake Inhibitors</p> <ul style="list-style-type: none"> ◆ Duloxetine 60mg Tablet ◆ Des-venlafaxine 50mg ER Tablet ◆ Venlafaxine 75mg & 150mg ER Capsule <p>Noradrenergic and Specific Serotonergic Antidepressants</p> <ul style="list-style-type: none"> ◆ Mirtazapine 15mg & 30mg Tablets <p>Melatonergic Agonist</p> <ul style="list-style-type: none"> ◆ Agomelatine 25 mg Tablet <p>Other Antidepressant</p> <ul style="list-style-type: none"> ◆ Vortioxetine 10mg Tablet
Distigmine Bromide 5 mg Tablet	<p>Myasthenia gravis</p> <ul style="list-style-type: none"> ◆ Pyridostigmine 60mg Tablet ◆ Neostigmine 2.5mg/mL Injection <p>Urinary retention and neurogenic bladder EXCLUDING intestinal atony:</p> <ul style="list-style-type: none"> ◆ Oxybutinin 5mg Tablet <p>Indication "intestinal atony"</p> <ul style="list-style-type: none"> ◆ Nil
Paraldehyde Injection	<ul style="list-style-type: none"> ◆ Diazepam 5mg Rectal Solution ◆ Diazepam 5mg/mL Injection ◆ Phenobarbitone 200mg/mL Injection ◆ Phenytoin 50mg/mL Injection ◆ Sodium Valproate 400mg Injection
Fluorouracil 100 mg Tablet	<ul style="list-style-type: none"> ◆ Fluorouracil 50mg/mL Injection (Multisource) ◆ Oxaliplatin 50mg Injection

PINDAAN FORMULARI UBAT KKM

Adapted from Circular FUKKM 01/2020

Drugs Approved to be Delisted from FUKKM

Drug Name	Alternative Drug Available in FUKKM
Levodopa 100 mg & Benserazide 25 mg Dispersible Tablet	<ul style="list-style-type: none">◆ Levodopa/Carbidopa 100/25 mg & 250/25mg Tablet◆ Levodopa 200 mg & Benserazide 50 mg Tablet◆ Levodopa 100 mg, Benserazide 25 mg HBS Capsule◆ Levodopa/Carbidopa/Entacapone 50/12.5/200mg, 100/25/200mg, 50/37.5/200mg & 200/50/200mg Tablet
Fludarabine Phosphate 10 mg Tablet	<ul style="list-style-type: none">◆ Fludarabine Phosphate 50mg Injection
Diclofenac 100mg Suppository	<ul style="list-style-type: none">◆ Diclofenac (12.5/ 25/ 50 mg) Suppository◆ Diclofenac 50 mg Tablet◆ Diclofenac Sodium 75 mg/3 ml Injection◆ Diclofenac 1% Gel

REFER TO PINDAAN/TAMBAHAN KEPADA FORMULARI UBAT KKM (FUKKM) BIL. 1 TAHUN 2020 FOR FULL INFORMATION @
([HTTPS://WWW.PHARMACY.GOV.MY/V2/EN/APPS/FUKKM](https://www.pharmacy.gov.my/v2/en/apps/fukkm))

PHARMACY ACTIVITIES

BENKEL PROPOSAL & PEMBENTANGAN KAJIAN PEGAWAI FARMASI PROVISIONAL (PRP) 01/2020



Facilitator:

PN AISYAH BINTI ALI
PEGAWAI PENYELIDIK
CRC HSIJB

DATE : 20 Julai 2020

VENUE: Auditorium Ixora, Hospital Permai Johor Bahru

STUDYTITLE	PRESENTER
1. Descriptive Analysis of Medication Errors Reported in Hospital Permai Johor Bahru from 2013-2018 (Final Results)	Fatin Nabilah Binti Abdul Rahman Muhammad Lutfi bin Mohd Fauzi
2. Hospital Resource Utilization of Paliperidone Palmitate Injection: Naturalistic Review from An Asian Mental Health Institution (Final Results)	Liew Yi Ling
3. Antipsychotic Induced Metabolic Side Effects among Forensic Psychiatric Patients in Hospital Permai Johor Bahru (Proposal)	Mohammad Zakwan Bin Ridzuan
4. Adverse Events Associated with Risperidone Use in Paediatric Patients: A Prospective Study (Proposal)	Fam Hwei Teng Syafizawati Binti Ghazali Tan Woei Yan
5. Pharmacists Attitude and Responsibilities Towards Off-Label Prescribing: A Cross-Sectional Study (Proposal)	Diviyasri Soundra Rajan Ng Hwee San

PHARMACY ACTIVITIES

KURSUS PENGURUSAN UBAT DI WAD DAN STOR TAHUN 2020



DATE : 10 August 2020

VENUE: Bilik Seminar 1 & 2, HPJB



COURSE OBJECTIVE :

- ⇒ The MAIN OBJECTIVE of this course is to provide an understanding of drug management in the ward and substor to healthcare workers, especially to Medical Assistants & Nurses in Hospital Permai.
- ⇒ Topics presented during the course include:
 - ◆ *Tatacara Pengurusan Stor & Sub-stor*
 - ◆ *Pemeriksaan Wad & Sub-stor*
 - ◆ *Pembekalan Ubat Psiktropik Ke Wad*
 - ◆ *Pengendalian Ubat "Cold Chain"*
 - ◆ *Pemantauan Suhu & Pembacaan Termometer*
 - ◆ *Sistem Pembekalan "Unit Of Dose"*
 - ◆ *Pengendalian Troli Ubat & Troli Kecemasan*
 - ◆ *Pembekalan Ubat Floor Stock & After Office Hour Stock*
 - ◆ *Therapeutic Drug Monitoring*

PHARMACY ACTIVITIES

KURSUS MEDICATION SAFETY TAHUN 2020



COURSE OBJECTIVE :

- ⇒ The MAIN OBJECTIVE of this course is to provide exposure to the participants on MEDICATION ERROR REPORTING, ADVERSE DRUG REACTION AND ALLERGY CARD.
- ⇒ The course speakers are Pharmacists from Drug Information Unit, Inpatient and Outpatient Pharmacy Units who are experienced in their respective fields.
- ⇒ Topics presented during the course include:
 - ◆ *Pengenalan Keselamatan Pengubatan*
 - ◆ *Pengenalan Polisi Medication Safety HPJB*
 - ◆ Adverse Drug Reaction (ADR) & Causality Assessment
 - ◆ *Pelaporan Medication Error*
 - ◆ Pengendalian ubat Look Alike, Sound Alike (LASA)
 - ◆ Panduan Tallman Lettering
 - ◆ Dilution Guide on High Alert Medications
 - ◆ Polisi Troli Kecemasan
 - ◆ Needle Syringe Labelling
 - ◆ Allergic Card

DATE : 25 August 2020

VENUE: Bilik Seminar 1 & 2, HPJB



